Kodu・Aktsiate loetelu・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Avatud

4.76

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.62

Max

4.84

Põhinäitajad
By Trading Economics
Sissetulek	143M 17M
P/E Sektori keskmine	2.462 57.371
Aktsiakasum	-0.36
Töötajad	7

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+75.62% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	4. nov 2026

Turustatistika
By TradingEconomics
Turukapital	8M 180M
Eelmine avamishind	4.76
Eelmine sulgemishind	4.76

Minerva Neurosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. aug 2026, 23:51 UTC

Bitcoin and Ethereum rise amid broader financial trends, while concerns over U.S. national debt and rising bond yields prompt Treasury interventions ahead of key economic data releases.

23. aug 2026, 23:51 UTC

Bitcoin and Ethereum rise amid concerns over U.S. national debt and bond market pressures, while Asian stocks anticipate recovery following positive U.S. market performance.

23. aug 2026, 23:51 UTC

Bitcoin and Ethereum rise as U.S. national debt hits $40 trillion, prompting concerns over economic stability and upcoming key economic data releases.

23. aug 2026, 23:51 UTC

Cryptocurrency prices rise amid U.S. national debt concerns and bond market volatility, as investors brace for major earnings reports and geopolitical tensions.

23. aug 2026, 23:51 UTC

Australia's Construction Output Expected to Rise 0.4% Amid Cautious Investor Sentiment Ahead of August Release

23. aug 2026, 23:51 UTC

Australia's RBA Trimmed Mean CPI Release on August 26, 2026, Expected to Reveal Key Insights into Core Inflation Trends Amid Global Economic Uncertainty.

23. aug 2026, 23:51 UTC

Australia's Inflation Rate Expected to Drop Slightly to 3.2% Amid Economic Shifts and Market Volatility Concerns

23. aug 2026, 23:51 UTC

Macro News

Bitcoin is higher today, continuing its upward trend since Saturday. Positive sentiment follows Wall Street's rebound amid declining interest rates and rising gold prices.

23. aug 2026, 23:51 UTC

Japan's Industrial Production Data Release on August 30 Expected to Show Continued Growth Amid Market Concerns.

23. aug 2026, 23:51 UTC

Japan's Retail Sales YoY Data Release on August 30 Expected to Show Significant Rebound Amid Mixed Economic Sentiment and Recent Stock Market Decline.

23. aug 2026, 23:41 UTC

Canada's Monthly GDP Growth Expected Amid Trade Tensions and Inflation Concerns Ahead of August 28 Release.

23. aug 2026, 23:41 UTC

Bank of Korea's Upcoming Interest Rate Decision Sparks Optimism Amid KOSPI Rally and Global Economic Trends

23. aug 2026, 23:41 UTC

Canada's GDP Growth Rate Faces Caution Amid Escalating U.S. Trade Tensions and Tariff Concerns Ahead of August 28 Release

23. aug 2026, 23:41 UTC

Canada's Q2 2026 GDP Growth Rate Release Amidst U.S. Trade Tensions and Infrastructure Boosts Scheduled for August 28, Heightening Market Scrutiny.

23. aug 2026, 23:31 UTC

RBA Bulletin Release on August 27, 2026 Sparks Anticipation Amid Global Decline in Interest Rates and Market Fluctuations.

23. aug 2026, 23:21 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Amid Mixed Sentiment and Economic Growth Concerns

23. aug 2026, 23:21 UTC

U.S. Goods Trade Balance Expected to Hit $99 Billion Deficit Amid Rising U.S.-Canada Tariff Tensions

23. aug 2026, 23:21 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% in July Amid Mixed Market Sentiment Ahead of August Release

23. aug 2026, 23:21 UTC

Canada's Current Account Deficit Expected to Reach -5.5 Billion CAD in Q2 2026 Amid Trade Tensions with U.S.

23. aug 2026, 23:21 UTC

The CAD/CHF currency pair is lower during after-market hours, reflecting a decline since Friday's close amid notable fluctuations in its one-month trading range.

23. aug 2026, 23:21 UTC

Correlated Moves

XRP is rising during Sunday’s session, supported by Bitcoin's upward movement. The asset has gained significantly since Saturday and remains above its 20-day moving average.

23. aug 2026, 23:11 UTC

EUR/NZD is trading higher in after-market hours, continuing a gradual increase since Friday's close, despite a recent trend of lower closes.

23. aug 2026, 23:11 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Inflation and Economic Uncertainty, According to S&P/Case-Shiller Index

23. aug 2026, 23:11 UTC

U.S. GDP Price Index QoQ 2nd Estimate Set for August 26, Forecasting a 0.063% Increase Amid Inflation Concerns and Mixed Market Sentiment

23. aug 2026, 23:11 UTC

South Africa's Trade Balance Data Release on August 28 Expected Amid Fluctuating Trends and Commodity Market Sentiment.

23. aug 2026, 23:01 UTC

Correlated Moves

Gold/Silver is trading lower, influenced by broader market sentiment and concerns over the U.S. national debt reaching $40 trillion. It remains below its 20-day moving average.

23. aug 2026, 23:01 UTC

Gold/NZD is trading higher since Friday's close, maintaining a position above its 20-day moving average amid concerns over the U.S. national debt reaching $40 trillion.

23. aug 2026, 23:01 UTC

Gold/JPY is trading higher, reflecting a broader positive performance. The asset remains significantly above its 20-day moving average, indicating strong underlying momentum.

23. aug 2026, 23:01 UTC

Gold/HKD is higher today, reflecting a strong trend above its 20-day moving average. Earlier, it reached a high of 2.16% above Friday's close.

23. aug 2026, 23:01 UTC

Gold/SGD is higher in the current session, maintaining a gain above its 20-day moving average despite a slight pullback from earlier peaks.

Võrdlus sarnastega

Hinnamuutus

Minerva Neurosciences Inc Prognoos

Hinnasiht

By TipRanks

75.62% tõus

12 kuu keskmine prognoos

Keskmine 8.5 USD 75.62%

Kõrge 10 USD

Madal 7 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Minerva Neurosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Minerva Neurosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Maksueelne kasum

Müük

Intressikulud võla pealt

Ärikasum

Ettevõttest Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.